Teosyal RHA Kiss 2x0.7ml
Important Notice
Medical device regulated by the European Medical Device Regulation (MDR), intended exclusively for authorized healthcare professionals. By purchasing, the customer declares to be authorized for their professional activity; false information may entail legal responsibilities.
Teosyal RHA® Kiss is the lip reference of the Resilient Hyaluronic Acid range: 23 mg/ml of hyaluronic acid with cross-linking below 5 %, in 0.7 ml syringes designed for the usual volume of a perioral treatment. The low chemical modification of the gel is particularly relevant in the lip, where the tissue is constantly deformed when speaking and smiling.
- HA 23 mg/ml
- Cross-linking < 5 % (NMR)
- Lidocaine 0.3 % (3 mg/ml)
- Contents 2 syringes × 0.7 ml
- Needles 4 × 30G ½"
- Duration 12–18 months
Composition and technology
- Cross-linked hyaluronic acid: 23 mg/ml.
- Degree of cross-linking: < 5 %, measured by nuclear magnetic resonance.
- Lidocaine hydrochloride: 0.3 % by mass (3 mg/ml).
- Residual BDDE: < 1 ppm.
- Phosphate buffer pH 7.3 q.s. for 0.7 ml.
- RHA technology (Resilient Hyaluronic Acid): Teoxane's patented manufacturing process (Preserved Network Technology) that applies minimal chemical modification and preserves the long hyaluronic acid chains. The result is a gel of low cross-linking (< 5 %) able to stretch and recover its shape with facial movement, instead of resisting it like a conventional rigid gel.
- Format: 0.7 ml syringe. The pack provides 1.4 ml in total, below the maximum of 2 ml recommended by the manufacturer for lips, which makes it easier to adjust the dose without leftover material.
Position within the Teosyal RHA range
| RHA 1 | HA 15 mg/ml · 1 ml · 30G ½" — superficial fine lines and skin quality · ≥ 12 months |
|---|---|
| RHA 2 | HA 23 mg/ml · 1 ml · 30G ½" — moderate wrinkles, midface and lips · 12–18 months |
| RHA 3 | HA 23 mg/ml · 1 ml · 27G ½" — deep wrinkles, midface volume and remodelling of the lower third · 12–18 months |
| RHA 4 | HA 23 mg/ml · 1.2 ml · 27G ½" — deep wrinkles in thick skin and remodelling of the facial contour · 15–18 months |
| RHA Kiss (this product) | HA 23 mg/ml · 0.7 ml · 30G ½" — perioral region and lips · 12–18 months |
All references of the RHA range share a degree of cross-linking below 5 %, determined by nuclear magnetic resonance, and 0.3 % lidocaine. Within that margin the cross-linking increases in steps: RHA 2 is the least cross-linked, RHA 3 occupies an intermediate position and RHA 4 is the most cross-linked (FDA, Summary of Safety and Effectiveness Data P170002). That progression determines the firmness of the gel, the needle gauge supplied and the injection depth.
RHA Kiss versus PureSense Kiss: the same perioral indication, a different gel philosophy. RHA Kiss provides 23 mg/ml with cross-linking < 5 % in 0.7 ml and a 30G ½" needle; PureSense Kiss provides 25 mg/ml with cross-linking < 10 % in 1 ml and a 27G ½" needle.
Indications and treatment areas
Indicated for the treatment of the perioral region: lips (including the philtrum) and oral commissures.
According to the manufacturer, the product creates a volume that corrects wrinkles and skin depressions and restores skin hydration; it may also add volume to the lip and enhance its contour.
Technique and treatment protocol
- Injection plane: slow injection at variable depth — dermis, subcutaneous plane, subdermis or submucosa.
- Needles included: 30G ½", two per syringe (4 per pack).
- Cannula: a valid alternative is a 25G blunt cannula; compatibility verified by the manufacturer with TSK 25G/50 mm.
- Maximum volume: 6 ml per session; in the lips a maximum of 2 ml is recommended.
- Estimated duration: between 12 and 18 months.
- Do not inject into the epidermis. Do not combine in the same session with peeling, laser or ultrasound.
Technical data
| Manufacturer | Teoxane SA (Laboratoires Teoxane), Geneva, Switzerland |
|---|---|
| Active substance | Cross-linked hyaluronic acid 23 mg/ml |
| Degree of cross-linking | < 5 % (NMR) |
| Anaesthetic | Lidocaine HCl 0.3 % by mass |
| Cross-linker | BDDE, residual < 1 ppm |
| Technology | RHA — Resilient Hyaluronic Acid |
| pH | 7.3 (phosphate buffer) |
| Presentation | 2 pre-filled syringes of 0.7 ml |
| Needles | 4 × 30G ½" (2 per syringe) |
| Compatible cannula | 25G (TSK 25G/50 mm verified) |
| Treatment plane | Dermis, subcutaneous, subdermis or submucosa |
| Estimated duration | 12–18 months |
| Classification | CE-marked medical device |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: between 2 °C and 25 °C, protected from direct sunlight.
- Do not use after the expiry date stated on the pack.
- Sterile single-use product. Do not reuse or re-sterilise the syringe or the needles.
- The pack contains: 2 pre-filled syringes of 0.7 ml, 4 sterile 30G ½" needles, and two traceability labels per syringe — one to be given to the patient and one for the medical record.
Contraindications and warnings
Contraindications: skin disorders, inflammation or infection in or near the treatment area; allergy to hyaluronic acid and a history of severe allergy or anaphylactic shock; allergy to lidocaine or to amide-type local anaesthetics; recent peel, laser or ultrasound treatment; autoimmune diseases; heart disease or treatment with beta-blockers; hepatocellular insufficiency or treatment for liver disease; epilepsy; porphyria; pregnancy, breastfeeding and patients under 18 years of age.
Vascular warning: intravascular injection may cause vascular occlusion, ischaemia and necrosis of the treated area. In the most serious cases it may lead to visual disturbances or blindness and to cerebral ischaemia or haemorrhage. Never inject intravascularly.
Before injection: do not treat if a dental procedure has been performed in the previous 15 days; avoid aspirin, anti-inflammatory drugs, anticoagulants and vitamin E during the preceding week; avoid alcohol and intense sun exposure on the previous day and on the day itself; remove make-up completely.
After injection: during the first 12 hours, do not apply make-up or undertake intense exertion; during the following week, avoid alcohol, prolonged sun or UV exposure, temperatures below 0 °C, sauna and hammam; for 15 days, do not undergo dental procedures or other aesthetic treatments.
Always consult the instructions for use included in the pack before treatment.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the official documentation of Teoxane SA (instructions for use TEOSYAL RHA KISS®, ref. 230577-00, and patient product information). This information sheet does not replace the instructions for use supplied with the product.